Â鶹ŮÓÅ

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Medicaid Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • Â鶹ŮÓÅ Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • High Postcancer Medical Bills
  • Federal Workers’ Health Data
  • Cyberattacks on Hospitals
  • ‘Cheap’ Insurance

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Wednesday, May 7 2025

Full Issue

Rite Aid Stores To Close Or Be Sold Amid Second Filing For Chapter 11

The drugstore chain intends to sell customer prescription files and inventory as it closes its distribution centers and store locations. Meanwhile, manufacturers have increased imports and are starting to stockpile as the threat of President Trump's pharmaceutical tariffs looms.

Rite Aid customers can expect their local store to close or change ownership in the next few months, as the struggling drugstore chain goes through another bankruptcy filing. The company plans to sell customer prescription files, inventory and other assets as it closes distribution centers and unloads store locations. Stores will remain open for now, but the company isn’t buying new inventory so bare shelves are likely become more common. (Murphy, 5/6)

More pharma and tech updates —

President Trump's threat of pharmaceutical tariffs is driving a surge of exports of drugs and medical products from Europe to the U.S. as manufacturers look to build up stockpiles before duties hit. (Reed, 5/7)

The pharmaceutical industry estimates President Donald Trump’s new drug pricing proposal could cost drug companies as much as $1 trillion over a decade, its largest trade group is telling members of Congress. The idea, first floated last week by the White House as a way to help pay for the president’s tax cut plan, blindsided the pharmaceutical industry and has prompted a furious lobbying campaign. (Cohrs Zhang, 5/6)

Providing kidney care is no longer about which company can open the most dialysis centers. Kidney care behemoth DaVita is investing in technology solutions to help its patients receive dialysis and kidney care at home if they choose, said CEO Javier Rodriguez. It’s part of the evolution of a nearly $13 billion company that formed 25 years ago and operates more than 2,500 dialysis centers in the U.S. (Perna, 5/6)

Many large drugmakers are still using a decades-old test — derived from horseshoe crabs — as a go-to tool for detecting contamination in medicines and vaccines, rather than switching to a cheaper and equally effective alternative, according to a survey by environmental groups. (Silverman, 5/6)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, April 22
  • Tuesday, April 21
  • Monday, April 20
  • Friday, April 17
  • Thursday, April 16
  • Wednesday, April 15
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 Â鶹ŮÓÅ